Mural Oncology is halting development of its lead IL-2 therapy and enacting major layoffs after its second trial failure this ...

After disappointing trial results for cancer treatments, Mural Oncology announced Wednesday it is cutting 90% of its ...

Shares of Mural Oncology MURA skyrocketed 134% on Tuesday after the company announced its decision to discontinue all ...

The writing is on the wall at Mural Oncology. Responding to clinical data, the biotech is laying off 90% of its employees and ...

Mural Oncology (MURA) announced that following review of data from its phase 2 ARTISTRY-6 trial in melanoma and previously announced results ...

Following review of data from the phase 2 ARTISTRY-6 trial and previously announced results from the phase 3 ARTISTRY-7 trial, Mural will ...

Shares of Mural Oncology plc (NASDAQ: MURA) are soaring Monday following the company's announcement that it will discontinue clinical development of its lead drug candidate Nemvaleukin and begin ...

US biotech Mural Oncology has halted all development of its lead candidate, nemvaleukin alfa, after the engineered cytokine ...

Real-time index price for TSX Oil and Gas EW Index (TXOE), along with buy or sell indicators, analysis, charts, historical ...

Mural Oncology plc said on Tuesday it would stop clinical development of its lead cancer treatment, nemvaleukin, and look into strategic alternatives for the company. Mural has brought on Lucid ...

Mural Oncology is winding down its lead clinical programme and enacting sweeping cuts to its workforce after its experimental cancer therapy, nemvaleukin, failed to deliver in two key studies.